All Articles

Primary adherence (prescription filled within 30 days) was lowest for self-pay patients and highest for commercially insured and Medicare Advantage patients for statins, antihypertensives, and diabetes medications.

Among patients with type 1 diabetes, inhaled insulin use was associated with a 0.68 percentage point reduction in average HbA1c, while injectable insulin was associated with a 0.82 percentage point reduction.

Use of suzetrigine, a non-opioid pain medication, has risen steadily each month since its approval in February 2025, with over half of the prescriptions occurring in July and August.

Hormone replacement therapy (HRT) prescriptions increased 72% from Q2 2021 to Q3 2025 among women aged 50 to 65, from 29.3 prescriptions per 1,000 women to 50.4 prescriptions per 1,000 women.

Among patients with polycystic ovary syndrome (PCOS), the median one-year weight change was an 11.5% loss for those treated with a GLP-1, compared to a 1.9% loss among those treated with metformin.

Children born to mothers diagnosed with intrahepatic cholestasis of pregnancy (ICP) were 31% more likely to have a motor delay diagnosed by age 5 compared to those born to mothers without a diagnosis of ICP.

Patients diagnosed with kidney cancer during the pandemic were 25% more likely to die in the three years following their diagnosis compared to those diagnosed before the pandemic.

In October, the weekly rate of medically attended hand, foot, and mouth disease (HFMD) reached more than three times the highest weekly rate in 2024 and nearly twice the highest weekly rate in 2023.

Total firearm injury rates nearly doubled during the COVID-19 pandemic, peaking at 1.8 per 1,000 emergency department (ED) visits in Q2 2020. These rates have since dropped and reached pre-pandemic levels by Q4 2023.

Nebraska and Kansas have the highest rates of Parkinson’s disease among U.S. states studied, with 620 and 596 people diagnosed per 100,000 patients, respectively. Even after adjusting for other factors like age, sex, and comorbidities, Nebraska and Kansas continue to have the highest rates among U.S. states, suggesting the elevation is not solely due to demographics.

Patients who are Black, patients who live in non-urban areas, and patients with diabetes each have an increased likelihood of stillbirth after 20 weeks gestation.

Among non-diabetic patients without chronic kidney disease (CKD), there was a minimal increase of 0.01 mg/dL to 0.02 mg/dL in serum creatinine in the months following initiation of semaglutide, liraglutide, or tirzepatide. Of note, creatinine values can vary up to 0.6 mg/dL and still be considered within the normal range.

The risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.

Women with a history of miscarriages who received progesterone in the year before their pregnancy were 18% less likely to experience a miscarriage than those who did not receive progesterone before their pregnancy.

Patients prescribed two concurrent QT-prolonging medications experienced ventricular tachycardia (a type of abnormal heart rhythm) and myocardial infarction at similar rates to patients prescribed only one such medication.

At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.

Neonatal sepsis diagnosis rates declined steadily from 2015 to 2023. The most pronounced reductions were among Black infants, whose sepsis rate dropped by nearly half, from 2.4% in 2015 to 1.3% in 2023.

The rate of opioid prescriptions at discharge after childbirth declined by 43% between 2017 and 2024, falling from 502 per 1,000 mothers to 285 per 1,000 mothers.

Vaccine effectiveness against RSV infection declined from 71% at 4 months post-vaccination to 40% by 19 months post-vaccination.

Patients on selective serotonin reuptake inhibitor (SSRI) antidepressants for three to eight years showed an 18% lower risk of developing hematologic cancer compared to those not on an SSRI.